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Correlation of Xpert MTB/RIF with 
measures to assess Mycobacterium 
tuberculosis bacillary burden in high 
HIV burden areas of Southern Africa
Fenella Beynon1, Grant Theron2, Durval Respeito3, Edson Mambuque3, Belen Saavedra3, 
Helder Bulo3, Sergi Sanz1, Keertan Dheda2 & Alberto L. Garcia-Basteiro1,3,4
Traditionally, smear microscopy has been used as a point-of-care measure of bacillary burden in 
tuberculosis patients to inform infection control and contact tracing. Xpert MTB/RIF has the potential 
to replace smear. However, data to support the use of its quantitative output [cycle threshold (CT)] as 
an alternate point-of-care measure of bacillary burden are limited. This study assessed the correlation 
(Spearman’s) between CT, smear, culture time-to-positivity (TTP), and clinical factors in patients with 
Xpert-positive sputum from Mozambique (n = 238) and South Africa (n = 462). Mean CT and smear 
grade correlated well (ρ0.72); compared to TTP and smear (ρ0.61); and mean CT and TTP (ρ0.50). In 
multivariate analyses, lower CT (higher bacillary load) was associated with negative HIV serostatus 
and low BMI. A smear positivity rule-out (95% sensitivity) CT cut-off of 28.0 was identified, with 54.1% 
specificity, 2.07 positive likelihood ratio, 0.09 negative likelihood ratio and 79.0% correctly classified. 
Cut-offs were higher for HIV positive compared to HIV negative individuals for any set sensitivity 
level. This study suggests Xpert CT values correlate well with smear, both in HIV positive and negative 
individuals, and that CT cut-offs might be broadly applicable to multiple settings. Studies to directly 
assess the association of CT with infectiousness are needed.
The bacillary burden of tuberculosis (TB) in sputum is a key marker of transmission risk and disease severity1–5. 
Until recently, smear microscopy has been the mainstay of rapid TB diagnosis but lacks sensitivity, particularly in 
people living with HIV. Smear status has been used as a marker of transmission risk for decades, on the basis that 
smear positive patients are more likely to be infectious, particularly at the highest grade6,7.
Culture remains the gold standard for TB diagnosis. Liquid culture using the mycobacterial growth indicator 
tube (MGIT) system (BACTEC) has a high sensitivity with the ability to detect down to 1 colony forming unit 
(CFU) per sample, using solid culture as a reference standard8. Time to positivity (TTP) of the MGIT system 
(the amount of time in culture until mycobacterium tuberculosis (MTB) is detected) has been shown to predict 
the risk of transmission9 and response to treatment10,11 more reliably than smear status. However, in low-income 
countries culture is often not available due to its high cost and requirement for strict biohazard precautions12. 
Moreover, TTP cannot be used to aid decision-making about transmission curbing as it takes days to weeks to 
obtain results.
In 2010, the World Health Organisation (WHO) endorsed the roll-out of Xpert® MTB/RIF13, a cartridge based 
automated polymerase chain reaction (PCR) system for the detection of MTB deoxyribonucleic acid (DNA). 
Xpert provides results in under 2 hours and can detect down to 100 CFU per sample8, improving the sensitivity 
for patients with low bacillary burden compared to smear microscopy14. It also provides a cycle threshold (CT) 
result, which reflects the number of PCR cycles required to detect MTB. Each subsequent cycle represents ~50% 
1ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. 2DST/NRF Centre of Excellence for Biomedical 
Tuberculosis Research, MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa. 3Centro 
de Investigação em Saude de Manhiça (CISM). Rua 12, Cambeve CP 1929, Maputo, Mozambique. 4Amsterdam 
Institute for Global Health and Development (AIGHD), Academic Medical Center, Amsterdam, The Netherlands. 
Correspondence and requests for materials should be addressed to A.L.G.-B. (email: alberto.garcia-basteiro@
manhica.net)
Received: 2 August 2017
Accepted: 6 March 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS |  (2018) 8:5201  | DOI:10.1038/s41598-018-23066-2
less starting material than the last, thereby providing a semi-quantitative result of bacillary burden, with higher 
CT results reflecting lower bacillary burden.
In-line with the WHO recommendation, 15 countries in one of the high-burden lists (TB, TB-HIV or 
MDR-TB) have now adopted Xpert as the initial diagnostic test for TB15. In these settings, there is a need for an 
alternative measure of bacillary burden that correlates with smear positivity to help predict transmission risk 
and disease severity. Xpert CT could potentially be used as such a measure until evidence is available that directly 
assesses the relationship between baseline Xpert CT and outcomes.
A small number of studies have demonstrated a correlation between TTP and CT results in pulmonary sam-
ples, suggesting that an assessment of bacillary burden can be made that is more precise than smear microscopy 
and cheaper and faster than culture8,16–19. However, Hanrahan et al. demonstrated that the correlation of TTP and 
CT is less strong among HIV positive individuals comparted to HIV negative individuals18. A recent meta-analysis 
identified cut-of CT values of 27.7 and 31.8 to predict smear positivity with 85% and 95% sensitivity respectively20.
In this study, we aimed to further evaluate the correlation between measures of bacillary burden and identify 
a cut-point for smear positivity using Xpert CT. We have done so through the inclusion of several study sites in 
Mozambique and South Africa in the context of a high HIV prevalence with a larger sample size than previous 
studies. Furthermore, we evaluated the effect of clinical features and symptomatology on the different measures 
of bacillary burden.
Methods
Study sites and design. The analysis was conducted on anonymised data from participants of larger 
TB studies conducted in Mozambique and South Africa with sputum samples positive for Xpert MTB/RIF. In 
Mozambique, consecutive individuals aged 15 or over presenting with possible TB to any of the 10 clinics in the 
catchment area of Manhiça District Hospital were recruited from August 2013 to August 2014. Manhiça District 
Hospital is located in a high HIV and TB burden area in Maputo Province, in the south of the country21. In South 
Africa, data from six studies that recruited consecutive patients with presumptive TB from primary care clinics 
or hospitals were included, four of which have been previously published17,22–24. While the district of Manhiça is a 
semi-rural area in Mozambique, the studies based in South Africa were conducted in the Cape Town metropole, 
yet both sites are in areas with high TB and HIV prevalence21,25.
Sociodemographic and clinical details including HIV status and CD4 count were collected for all participants 
with TB from standardised questionnaires at the time of diagnosis and clinical records. HIV testing was offered 
to those without a known result within the last three months.
Informed consent was obtained for all participants. The Mozambique study was approved by the CISM 
Scientific Committee, the CISM Institutional Review Board and the National Bioethics Committee of 
Mozambique; the South African studies were approved by the University of Cape Town Faculty of Health Sciences 
Ethics Committee and the City of Cape Town. All study methods were carried out in accordance with the relevant 
guidelines and regulations established by the National Bioethics Committees in Mozambique and South Africa.
Data availability statement. The datasets generated during the current study are kept at the data center 
of CISM. An anonymized version of the dataset can be made available upon request to CISM’s Internal Scientific 
Committee (Email: cci@manhica.net).
Diagnostic tests and measures of bacillary burden. All participants in Mozambique had two samples 
taken, which were pooled and centrifuged and tested for both smear microscopy (Ziehl Neelsen) and Xpert 
(MTB/RIF G4 cartridge Cepheid, Sunnyvale, CA). All participants in South Africa had at least one (maximum 3) 
sample tested using fluorescence microscopy and Xpert. If more than one smear result was available, the highest 
smear grade was used. Smear microscopy results were graded using the International Union Against Tuberculosis 
and Lung Disease standard26. The mean CT (of positive probes A-E) was recorded for those with positive Xpert 
results. Liquid culture (BACTEC MGIT 960, BD Diagnostics, Franklin Lakes, NJ) was done, after decontamina-
tion with NALC-NaOH, only for those with a positive Xpert result and/or those who had been treated for TB in 
the past (for a minimum of 4 weeks). TTP (from starting the culture to positive results) was recorded in days.
The sample for this study included only patients with pulmonary samples who had positive Xpert results and 
an available smear result. Those with rifampicin resistance were excluded as the CT of the probe(s) detecting 
resistance have values ≥ 4 CT from any other27, which could skew the mean CT value of the probes. Those with a 
CT ≥ 34 for the internal positive control (IPC) – a measure of the presence of inhibitors – were also excluded as 
this has previously been shown to affect the quantitative ability of Xpert19.
Data analysis. Data was analysed using Stata 13.1 (StataCorp, College Station, Texas, USA). Descriptive 
analysis was carried out and differences were assessed between study sites and according to HIV status. The 
distributions of CT and TTP values were assessed and, as they did not follow a normal distribution, a nonpara-
metric equality of medians test was used to assess differences by HIV status, CD4 count and other clinical factors 
including symptoms. Differences in smear positivity were assessed using chi-squared. Correlation between TTP, 
CT and smear grade were assessed using Spearman’s ρ with 95% confidence intervals for all participants and by 
study site and HIV status. In case no statistical differences in the correlation of Xpert CT and smear grade or TTP 
were observed, estimates for the optimal cut off for smear positivity could be estimated with data from both sites.
Optimum cut-off for smear positivity (considering as all smears scanty to 3+ as positive) was calculated using 
a receiver operating characteristic (ROC) curve. The cut-off to detect smear positivity with 99%, 95%, 90% and 
85% sensitivity (for use as a ‘rule-out’ cut-off) were derived from the combined data set and evaluated for sen-
sitivity, specificity, negative and positive likelihood ratios and percentage of tests correctly classified overall and 
according to HIV status. Differing levels of CT cut-offs were also assessed for sensitivity, specificity, negative and 
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positive likelihood ratios and percentage of tests correctly classified overall and according to HIV status. Rule-in 
CT cut-offs (95% specificity for smear positivity) were not calculated due to their poor clinical utility – previous 
studies have demonstrated a high degree of misclassification of smear positives as smear negative28. Univariate 
regression analysis was conducted to identify variables associated with measures of bacillary burden (age, sex, 
type of sample, history of prior treatment, HIV status, CD4 count, anti-retroviral therapy (ART), body mass index 
(BMI), presence and duration of constitutional symptoms or cough) and study site. Multivariate regression anal-
ysis was conducted including variables with p < 0.10 from univariate analysis. Bidirectional stepwise multivariate 
regression analysis was also conducted to ensure the validity of this approach.
Results
Baseline characteristics. Seven hundred Xpert positive participants were included – 238 (34.0%) from 
Mozambique and 462 from South Africa. Participant characteristics according to each site are shown in Table 1. 
Median age was 35 years (IQR 28–44) and 404 (58.1%) were men. A prior history of TB treatment was found in 
29.1% of patients. Co-infection with HIV was common (57.2%) with significant immunosuppression – median 
CD4 was 173 (IQR 69–336).
Symptoms were common: cough was present in 614/697 (88.1%) participants with documented history; fever 
in 347/592 (58.6%); weight loss in 609/700 (87.0%); and night sweats in 574/700 (82.0%). There were significant 
variations in symptomatology between study sites (Supplementary Table S1). There were also differences between 
HIV positive and negative participants. Participants with HIV coinfection were more likely to have productive 
cough (85.0% vs 76.6%, p 0.010); weight loss (90.5% vs 82.9%, p 0.003); and fatigue (73.7% vs 61.1, p < 0.001); but 
less likely to have chest pain (45.5% vs 62.3%, p < 0.001).
Measures of bacillary burden. Sputum smear was positive in 68.4% of participants; a greater propor-
tion were smear positive in the South Africa cohort (72.0%) than the Mozambique cohort (61.8%), p < 0.001. 
Culture was positive in 90.1% of cases with a median TTP of 10 (IQR 7–15), which was significantly shorter in the 
Mozambique cohort than the South African – 7.5 (5.3–11.6) vs. 12.0 (7.0–16.0), p < 0.001. Mean CT was slightly 
lower in the Mozambique cohort – 20.1 (15.7–26.6) vs 21.6 (17.6–26.8), p 0.016.
Study site
TotalMozambique South Africa
n = 238 n (%)/median (IQR) n = 462 n(%)/median(IQR) n = 700
Age 35.0 (29–46) 35.6 (28–44) 35.3 (28–45)
Sex
  Female 101 (42.4) 191 (41.7) 292 (42.0)
  Male 138 (57.6) 267 (58.3) 404 (58.1)
Previous TB
  No 207 (87.0) 289 (62.6) 496 (70.9)
  Yes 31 (13.0) 173 (37.5) 204 (29.1)
HIV
  Negative 58 (24.7) 235 (52.3) 293 (42.8)
  Positive 177 (75.3) 214 (47.7) 391 (57.2)
CD4
  <200 85 (56.7) 118 (58.1) 203 (57.5)
  ≥200 65 (43.3) 85 (41.9) 150 (42.5)
On ART
  No 88 (57.9) 122 (70.1) 210 (64.4)
  Yes 64 (42.1) 52 (29.9) 116 (35.6)
Smear Grade
  Negative 91 (38.2) 127 (28.0) 218 (31.6)
  Scanty 7 (2.9) 63 (13.9) 70 (10.1)
  1+ 34 (14.3) 85 (18.8) 119 (17.2)
  2+ 45 (18.9) 78 (17.2) 123 (17.8)
  3+ 61 (25.6) 100 (22.1) 161 (23.3)
MGIT
  Negative 9 (3.8) 38 (8.3) 47 (6.8)
  Positive 207 (87.0) 420 (91.7) 627 (90.1)
  Contaminated 22 (9.2) 0 22 (3.2)
  TTP 7.5 (5.3–11.6) 12.0 (7.0–16.0) 10 (7–15)
  Mean CT 20.1 (15.7–26.6) 21.6 (17.6–26.8) 21.2 (17.0–26.8)
Table 1. Participant characteristics by study site and overall (n = 700).
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Factors affecting bacillary burden.  Factors associated with bacillary burden varied according to the indi-
vidual measure (Supplementary Table S2). In univariate regression analysis only age, HIV and BMI were signif-
icantly associated with smear status, but symptoms of cough, productive cough, fever, weight loss, fatigue and 
chest pain as well as HIV, CD4, age, a prior history of TB and low BMI were variably associated with CT and TTP. 
In multivariate regression analyses (Table 2), lower bacillary burden (higher mean CT, higher TTP and smear 
negativity) was associated with positive HIV status: mean CT – B coefficient 2.59 [95% CI 1.58–3.59]; TTP – B 
coefficient 1.72 [0.33 to 3.11]; smear – OR 0.46 [95% CI 0.31–0.68]. Mean CT was also associated with fever – B 
coefficient −1.27 [95% CI −2.28 to −0.27], cough – B coefficient −4.50 [−7.84 to −1.17] and BMI – B coefficient 
2.23 [1.20 to 3.25] i.e. higher bacillary burden was associated with the presence of fever and cough and BMI of 
<18.5. TTP was also associated with study site – B coefficient 4.73 [3.32–6.13]. Smear was also associated with 
BMI – OR 0.63 [95% CI 0.43 to 0.92] and study site OR 1.54 [1.06 to 2.24].
Correlation of measures of bacillary burden. Figure 1 demonstrates the variation of mean CT accord-
ing to smear grade and correlation of mean CT with TTP. Smear negative samples had a median CT of 28.4 (IQR 
24.2–31.44) compared to 18.7 (15.8–22.6) for smear positive samples. Mean CT and smear grade (n = 700) were 
the most closely correlated measures of bacillary burden (Spearman’s ρ 0.72 (95% CI 0.68–0.76); Mozambique ρ 
0.76 (0.71–0.81); South Africa ρ 0.71 (0.66–0.75)). TTP correlated with smear grade (n = 620) with a Spearman’s 
ρ of 0.61 (0.56–0.66) (Mozambique 0.56 (0.45–0.64); South Africa 0.70 (0.65–0.75)). Mean CT and TTP (n = 620) 
correlated least well with a ρ of 0.50 (0.44–0.56) (Mozambique 0.60 (0.51–0.68); South Africa 0.44 (0.36–0.52). 
Correlation varied by HIV co-infection – for mean CT and smear grade, Spearman’s ρ were 0.64 (0.57–0.70) for 
HIV negative participants and 0.74 (0.69–0.78) for HIV positive participants; TTP and smear grade Spearman’s ρ 
0.63 (0.55–0.69) and 0.58 (0.51–0.65); and mean CT and TTP Spearman’s ρ 0.37 (0.26–0.47) and 0.56 (0.48–0.63) 
for HIV negative and positive respectively (Table 3).
CT cut-off for smear positivity.  Figure 2 shows the ROC curve analysis of CT threshold for smear pos-
itivity for overall data (area under the curve of 0.87). From the ROC curve analysis, a CT cut-off value of 28.0 
was identified with 95% sensitivity for smear positivity. Analysis according to HIV status found a lower cut-off 
for HIV negative individuals and higher cut-off for HIV positive individuals. Cut-offs with differing levels of 
sensitivity are reported in Table 4 (overall and according to HIV status) with associated, specificity, positive and 
negative likelihood ratios and percentage of correctly classified (with positive and negative predictive values in 
Supplementary Table S3. These are also presented according to different CT cut-offs between 25 and 30 in Table 5 
and Supplementary Table S4. Cut-offs of 31.8 and 27.7 (sensitivity of 95%, specificity of 35% and sensitivity 85%, 
specificity 67%) identified by the recent meta-analysis of CT predictors of smear positivity20, resulted in sensitivity 
of 98.8%, specificity 22.0% with a cut-off of 31.8 and sensitivity of 94.2% and specificity of 58.3% in this study.
Mean CT TTP Smear positivity
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Β coefficient 
(95% CI) p
Β coefficient 
(95% CI) p
Β coefficient 
(95% CI) p
Β coefficient 
(95% CI) p
Odds Ratio 
(95% CI) p
Odds Ratio 
(95% CI) p
HIV
Negative Ref Ref Ref Ref Ref Ref
Positive 2.4(1.46 to 3.33) <0.001
2.59
(1.58 to 3.59) <0.001
1.59
(0.35 to 2.82) 0.011
1.72
(0.33 to 3.11) 0.015
0.39
(0.28 to 0.56) <0.001
0.46
(0.31 to 0.68) <0.001
Fever
No Ref Ref Ref Ref
Yes −1.35(−2.36 to −0.33) 0.01
−1.27
(−2.28 to −0.27) 0.013
−2.79
(−4.15 to −1.43) <0.001
1.18
(0.83 to 1.66) 0.36
Cough
No Ref Ref Ref Ref
Yes −3.29(−4.72 to −1.87) <0.001
−4.5
(−7.84 to −1.17) 0.008
1.84
(−0.04 to 3.73) 0.06
0.67
(0.40 to 1.14) 0.14
BMI
<18.5 Ref Ref Ref Ref Ref
≥18.5 2.24(1.19 to 3.28) <0.001
2.23
(1.20 to 3.25) <0.001
2.14
(0.72 to 3.57) 0.003
0.69
(0.47 to 1.00) 0.048
0.63
(0.43 to 0.92) 0.019
Study site
Moz Ref Ref Ref Ref Ref
SA 1.1(0.12 to 2.08) 0.028 (−0.89 to 1.38)
3.37
(2.11 to 4.17) <0.001
4.73
(3.32 to 6.13) <0.001
3.37
(2.11 to 4.17) <0.001
1.54
(1.06 to 2.24) 0.024
Table 2. Multivariate regression analysis of factors significantly associated with higher sputum bacillary burden 
according to mean CT of Xpert MTB/RIF, MGIT TTP and sputum smear microscopy.
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Discussion
This study has added to the evidence that Xpert MTB/RIF CT can be used as a measure of bacillary burden that 
correlates well with smear grade and moderately with TTP in liquid culture. Given the current recommendation 
to replace smear with Xpert as the initial diagnostic test for TB and the lack of access to (and delay in obtaining) 
results from culture in LICs, Xpert may provide the only means for assessing bacillary burden for many countries.
This study identified a cut-off of 28 to rule-out smear positivity from studies in high HIV burden settings in 
Southern Africa. In studies reported by Hanrahan et al.18, Theron et al.28,29 and meta-analysis by Lange et al.20, 
variation of CT values occurs within smear grades and the CT cut-point to rule-out smear positivity varied from 
27.7 to 31.8. This may be attributable to a number of factors such as variation in HIV prevalence and differences in 
type of smear microscopy performed. The sensitivity of any particular cut-off value of mean CT varied according 
to HIV status, with lower sensitivity for HIV positive individuals. This may be due to the lower bacillary burden 
in HIV positive individuals as reflected by higher rates of smear negativity, and higher mean CT and TTP values.
Figure 1. (A) Boxplot of mean cycle threshold (CT) – (average of positive Xpert MTB/RIF probes) according 
to smear grade and (B) Correlation between mean cycle threshold (CT) and time to culture positivity (TTP) in 
days.
Overall Mozambique South Africa HIV negative HIV positive
* n = 700 * n = 238 * n = 462 * n = 293 * n = 391
§ n = 620 § n = 207 § n = 413 § n = 266 § n = 339
ρ (95% CI) ρ (95% CI) ρ (95% CI) ρ (95% CI) ρ (95% CI)
Mean CT & smear (n = *) 0.72 (0.68–0.76) 0.76 (0.71–0.81) 0.71 (0.66–0.75) 0.64 (0.57–0.70) 0.74 (0.69–0.78)
TTP & smear (n = §) 0.61 (0.56–0.66) 0.56 (0.45–0.64) 0.70 (0.65–0.75) 0.63 (0.55–0.69) 0.58 (0.51–0.65)
Mean CT & TTP (n = §) 0.50 (0.44–0.56) 0.60 (0.51–0.68) 0.44 (0.36–0.52) 0.37 (0.26–0.47) 0.56 (0.48–0.63)
Table 3. Correlation of measures of bacillary burden (Spearman’s ρ) with 95% confidence intervals for all 
samples and according to study site and HIV status.
Figure 2. ROC curve analysis showing sensitivity for differing mean cycle threshold (CT) – (average of positive 
Xpert MTB/RIF probes) values as a test for smear positivity.
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Whilst the majority of transmission occurs from individuals with higher smear grades, on which the basis 
of isolation and contact tracing for smear positive cases has been founded, some transmission does occur from 
smear negative individuals30,31. Factors contributing to this include intensity and duration of exposure, host sus-
ceptibility and discordance between sputum and cough aerosol bacillary burden32. Variation within the broad 
CT cut-
off
Sensitivity % (95% 
CI)
Specificity % (95% 
CI)
Positive LR (95% 
CI)
Negative LR (95% 
CI)
Correctly classified 
% (95% CI)
Cut-off for 99% sensitivity
Overall 
(n = 700) 32.6 99.0 (97.6–99.7) 15.6 (11.1–21.1) 1.17 (1.11–1.24) 0.07 (0.03–0.17) 73.0 (69.6–79.3)
HIV negative 
(n = 293) 29.6 99.1 (96.9–99.9) 31.7 (20.3–45.0) 1.45 (1.22–17.2) 0.03 (0.01–0.11) 85.3 (80.8–89.2)
HIV positive 
(n = 391) 32.9 99.2 (97.0–99.9) 11.6 (7.0–17.7) 1.12 (1.06–1.19) 0.07 (0.02–0.31) 64.5 (59.5–69.2)
Cut-off for 95% sensitivity
Overall 28.0 95.0 (92.7–96.8) 54.1 (47.3–60.9) 2.07 (1.79–2.40) 0.09 (0.06–0.14) 82.3 (79.3–85.0)
HIV negative 
(n = 293) 27.3 95.3 (91.7–97.6) 48.3 (35.2–61.6) 1.84 (1.44–2.36) 0.10 (0.05–0.18) 85.7 (81.1–89.5)
HIV positive 
(n = 391) 29.2 95.3 (91.8–97.7) 47.7 (39.7–55.9) 1.82 (1.57–2.13) 0.10 (0.05–0.18) 76.5 (72.0–80.6)
Cut-off for 90% sensitivity
Overall 26.3 90.3 (87.2–92.8) 65.1 (58.4–71.5) 2.59 (2.15–3.11) 0.15 (0.11–0.20) 82.4 (79.4–85.2)
HIV negative 
(n = 293) 25.2 90.1 (85.6–93.6) 66.7 (53.3–78.3) 2.70 (1.89–3.88) 0.15 (0.10–0.23) 85.3 (80.8–89.2)
HIV positive 
(n = 391) 27.1 90.3 (85.7–93.7) 64.5 (56.4–72.0) 2.54 (2.05–3.16) 0.15 (0.10–0.23) 80.1 (75.7–83.9)
Cut-off for 85% sensitivity
Overall 24.6 85.1 (81.6–88.1) 72.0 (65.6–77.9) 3.04 (2.45–3.77) 0.21 (0.17–0.26) 81.0 (77.9–83.8)
HIV negative 
(n = 293) 23.5 85.0 (79.7–89.3) 73.3 (60.3–83.9) 3.18 (2.09–4.86) 0.20 (0.15–0.29) 82.6 (77.8–86.8)
HIV positive 
(n = 391) 25.6 85.6 (80.5–89.8) 71.6 (63.8–78.6) 3.01 (2.34–3.89) 0.20 (0.15–0.28) 80.1 (75.7–83.9)
Table 4. Cut-points of mean CT to rule-out smear positivity (with varying degrees of sensitivity). Sensitivity, 
specificity, positive likelihood ratio (LR), negative LR and percentage of results correctly classified reported 
according to overall results (n = 700), HIV negative participants (n = 293) and HIV positive participants 
(n = 391).
CT cut-
off
Sensitivity % (95% 
CI)
Specificity % (95% 
CI)
Positive LR % (95% 
CI)
Negative LR % 
(95% CI)
Correctly classified 
%(95% CI)
Overall
25
86.5 (83.1–89.4) 71.6 (65.1–77.5) 3.05 (2.46–3.77) 0.19 (0.15–0.24) 81.9 (78.8–84.6)
HIV negative 89.7 (85.1–93.3) 66.7 (53.3–78.3) 2.69 (1.88–3.86) 0.15 (0.10–0.23) 85.0 (80.4–88.9)
HIV positive 83.5 (78.1–88.0) 72.9 (65.2–79.7) 3.08 (2.36–4.01) 0.23 (0.17–0.31) 79.3 (74.9–83.2)
Overall
26
89.2 (86.1–91.8) 68.8 (62.2–74.9) 2.86 (2.34–3.49) 0.16 (0.12–0.21) 82.9 (79.9–85.6)
HIV negative 91.4 (87.1–94.7) 61.7 (48.2–73.9) 2.39 (1.73–3.30) 0.14 (0.09–0.22) 85.3 (80.8–89.2)
HIV positive 86.9 (81.9–90.9) 71.0 (63.1–78.0) 3.00 (2.33–3.85) 0.18 (0.13–0.26) 80.6 (76.3–84.4)
Overall
27
92.1 (89.3–94.4) 60.6 (53.7–67.1) 2.34 (1.98–2.76) 0.13 (0.09–0.18) 82.3 (79.3–85.0)
HIV negative 94.0 (90.1–96.7) 48.3 (35.2–61.6) 1.82 (1.42–2.33) 0.12 (0.07–0.22) 84.6 (80.0–88.6)
HIV positive 89.8 (85.3–93.4) 64.5 (56.4–72.0) 2.53 (2.04–3.14) 0.16 (0.11–0.23) 79.8 (75.5–83.7)
Overall
28
95.0 (92.7–96.8) 54.1 (47.3–60.9) 2.07 (1.79–2.40) 0.09 (0.06–0.14) 82.3 (79.3–85.0)
HIV negative 97.0 (93.9–98.8) 40.0 (27.6–53.5) 1.62 (1.31–1.99) 0.08 (0.03–0.17) 85.3 (80.8–89.2)
HIV positive 92.8 (88.7–95.8) 59.4 (51.2–67.2) 2.28 (1.88–2.77) 0.12 (0.08–0.20) 79.5 (75.2–83.4)
Overall
29
96.5 (94.4–97.9) 45.9 (39.1–52.7) 1.78 (1.58–2.02) 0.08 (0.05–0.13) 80.7 (77.6–83.6)
HIV negative 97.9 (95.1–99.3) 35.0 (23.1–48.4) 1.51 (1.25–1.81) 0.06 (0.02–0.16) 85.0 (80.4–88.9)
HIV positive 94.9 (91.3–97.4) 49.7 (41.6–57.8) 1.89 (1.61–2.21) 0.10 (0.06–0.18) 77.0 (72.5–81.1)
Overall
30
97.5 (95.7–98.9) 39.9 (33.4–46.7) 1.62 (1.45–1.81) 0.06 (0.03–0.11) 79.6 (76.4–82.5)
HIV negative 99.1 (96.9–99.9) 28.3 (17.5–41.4) 1.38 (1.18–1.62) 0.03 (0.01–0.13) 84.6 (80.0–88.6)
HIV positive 95.8 (92.4–98.0) 43.9 (35.9–52.1) 1.71 (1.48–1.97) 0.10 (0.05–0.18) 75.2 (70.6–79.4)
Table 5. Sensitivity, specificity, positive likelihood ratio (LR), negative LR and percentage of results correctly 
classified reported according to different cut-points of mean CT by overall results (n = 700), HIV negative 
participants (n = 293) and HIV positive participants (n = 391).
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categorization of smear grades may also contribute to this and a more precise measure of bacillary burden by 
Xpert CT could therefore prove useful in more accurately identifying those with the highest risk of transmission 
at the time of diagnosis to prioritise infection control measures. Until that time, rule-out CT cut-offs have a greater 
utility than rule-in tests from a public health perspective: while rule-in cut-offs have a high specificity, they have 
poor sensitivity and therefore misclassify potentially infectious smear positive cases as smear negative28.
Baseline TTP is a better determinant than smear status of the risk of transmission9 and response to treat-
ment4,10,11 but its cost and need for specialist laboratories and training are prohibitive and it is therefore used 
infrequently in many settings. Exemplifying this is the fact that among the 22 high TB burden countries, there 
are only 1.8 laboratories able to perform TB culture per 5 million population12. Using CT as a same-day measure 
of bacillary burden that correlates with TTP could provide a useful and more timely surrogate. Unfortunately, CT 
has been found to have variable correlation with TTP. In some studies, this correlation has been adversely affected 
by HIV coinfection18, likely due to the lower bacillary burden in these individuals. In this study, the correlation 
between CT and TTP was stronger in HIV positive compared to HIV negative individuals. This could possibly be 
due to a difference in viable bacilli according to immunosuppression, with potentially a greater number of live 
bacilli in HIV positive individuals. CT likely correlates more closely with smear given that both methods detect 
both viable and non-viable organisms compared to culture which only detects viable organisms. This is reflected 
in the finding that Xpert remains positive beyond culture conversion33 and patients with previously treated TB are 
more likely to have Xpert-positive, culture-negative results34. Ultimately, studies to directly assess outcomes and 
transmission based on CT results would be helpful in understanding its utility in clinical practice.
In seeking to develop understanding of the effect of different clinical factors on bacillary burden by these 
different methods, this study found that many symptoms of TB were associated with higher bacillary burden, 
however many of their effects on bacillary burden were not present in multivariate analysis suggesting that other 
factors contribute to this association, including HIV. In multivariate analysis, the only factors remaining signifi-
cant for higher bacillary burden were HIV (negative), fever, cough, low BMI and study site. This likely reflects the 
increased severity of pulmonary disease and therefore a higher sputum bacillary load. Given that fever and BMI 
were associated with higher bacillary burden as measured by TTP, it may be valuable to consider them as clinical 
indicators of increased disease severity and transmission. Association of bacillary burden with study site may rep-
resent differences in the patient population not accounted for in the analysis (e.g. differences in disease severity 
or presence of pulmonary cavities. Although in general the diagnostic procedures were the same, there might still 
be subtle differences in laboratory processing techniques, samples chosen for culture/Xpert or different expertise 
of lab technologists involved which may also contribute to the findings. As Xpert mean CT was not associated 
with study site, which may reflect the lower inter-operator variability compared to smear and TTP. Correlations 
between measures of bacillary burden may also be affected by calibration, laboratory processing techniques or 
differences in the frequency of non-culturable bacilli between populations due to factors leading to immune sys-
tem containment such as HIV or TB treatment.
Beyond the potential differences by study site in the diagnostic procedures specified previously, this analysis 
had several limitations. Both sites have high HIV prevalence and are within Southern Africa, therefore it is possi-
ble that the findings are not applicable to other settings. Only patients with positive Xpert results were included; 
culture was not performed on all individuals in the larger study of patients with suspected TB, a reflection of 
real-world practice in this context. It was therefore not possible to evaluate the TTP for those who were Xpert 
negative, however these patients are likely to have lower bacillary burden and therefore present a lower trans-
mission risk. However Xpert negative patients have a lower risk of adverse outcomes35,36. The study population 
therefore reflected a population with higher risk of adverse outcomes, in whom measurements of bacillary burden 
are likely to be more important.
Another limitation of the study was the exclusion of extra-pulmonary samples due to their very small number 
in the larger study population. Few studies to date have assessed this and found the correlation to be lower in 
extra-pulmonary samples, but further larger studies are warranted to assess whether CT is reliable as a measure of 
bacillary burden in specific types of extrapulmonary sample16,29. In addition, transmission is almost exclusively 
from TB in sputum, reinforcing the greater need to understand bacillary burden in pulmonary samples.
With the introduction of Xpert Ultra recently recommended by WHO37, further studies are needed to evaluate 
the correlation of Xpert Ultra’s CT with TTP and smear. However, whilst programmes continue to use Xpert MTB/
RIF these findings remain applicable.
Conclusion
This study suggests that Xpert CT can be used as a measure of bacillary burden and a surrogate for smear status, 
with the recommended cut-off of 28 to rule-out smear positivity. However there is variation in the recommended 
cut-off between studies which may reflect differences in clinical features of the population. The exact cut-off point 
that individual national TB programmes that have replaced smear with Xpert will also depend on the specific 
desire for sensitivity and specificity. However, until studies have been conducted that directly assess the value 
of CT with outcomes and transmission of TB, CT values could be viewed as a measure of bacillary burden, with 
lower CT values representing a higher transmission risk, for programmes that no longer utilise smear microscopy.
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